文献速递治疗药物监测与药物基因组学特殊人群用药

英国国家医疗服务体系药物基因组学实施进展

Pharmacogenomics in the UK National Health Service: Progress towards implementation.
PubMed 文献 · Br J Clin Pharmacol · 2025-06-03

本文介绍英国国家医疗服务体系(NHS)药物基因组学实施进展,基于2024年成立的PGx-NoE两次利益相关方会议产出,围绕遗传、数据和服务三大领域提出具体建议,并提及PROGRESS研究信息学模式及CERSI中心等举措。

要点

  • NHS英格兰药物基因组学与药物优化卓越网络(PGx-NoE)2024年启动并召开两次会议。
  • 实施建议聚焦遗传、数据和服务三个关键领域,强调可操作推荐。
  • PROGRESS研究展示信息学模式,CERSI将制定英国特异性指南。

核心结论

  • 英国在药物基因组学实施方面已取得进展,许多明确障碍近年已被解决,有机会成为基因组学知情医疗的全球领导者。

研究设计与样本

  • 本文描述PGx-NoE于2024年与英国药物遗传学与分层医学网络及英国药理学会合作召开的两次利益相关方会议的产出。

主要发现

  • 会议产出围绕遗传、数据和服务三个关键领域提出 tangible 建议和实际实施措施。
  • PROGRESS研究展示了原理验证的信息学模式。
  • CERSI药物基因组学卓越中心将创建英国特异性指南并阐明复杂监管路径。

临床怎么用

  • 临床可关注NHS英格兰基因组检测目录及PGx-NoE推荐,推动基因信息指导处方。
  • 参考PROGRESS研究的信息学模式整合基因数据与处方系统。
  • 关注CERSI将发布的英国特异性药物基因组学指南以指导复杂监管路径。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the past decade there has been considerable and growing enthusiasm about the promise of using genomics to inform healthcare. In particular, using genetic data to inform prescribing practice has emerged as a compelling policy priority for health systems around the world, not least in the NHS. Various initiatives and strategies have been developed to explore the value of pharmacogenomics in the UK National Health Service (NHS) and identify strategies for implementation. The NHS England Network of Excellence for Pharmacogenomics and Medicines Optimisation (PGx-NoE) was launched in 2024 and held two stakeholder meetings over the year in collaboration with the UK Pharmacogenetics and Stratified Medicine Network and the British Pharmacological Society (BPS). This article describes the outputs of those meetings, which are discussed in the context of previously identified challenges and opportunities. Rather than simply identify further barriers or facilitators, outputs are contextualized around tangible recommendations and real-world implementation exercises. These are grouped into three key areas: genetics, data and service. The work of partners across the UK are highlighted, including development of the NHS England Genomic Test Directory, the proof-of-principle informatic patterns demonstrated by the PROGRESS study, and the launch of the Centre for Excellence in Regulatory Science and Innovation (CERSI) in Pharmacogenomics, which will create UK-specific guidance and clarify complex regulatory pathways. Many of the well-defined barriers to the implementation of pharmacogenomics have been addressed in recent years, and this work highlights how the UK has the opportunity to emerge as a global leader in genomics-informed healthcare.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. McDermott JH, Tsakiroglou M, Newman WG, et al. Pharmacogenomics in the UK National Health Service: Progress towards implementation. Br J Clin Pharmacol. 2025. PMID: 40460990. doi:10.1002/bcp.70109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。